|
# # # # An Australian charity seeking to find disease modifying therapies for Parkinson’s – The Shake It Up Australia Foundation – has announced a commitment to partially fund a clinical trial with a biotech firm called Anavex Life Sciences. The trial will focus on a drug called ANAVEX2-73 (also known as ‘blarcamesine’). This experimental treatment is a Sigma-1 receptor agonist In today’s post, we will discuss what the Sigma-1 receptor does, we will review some of the Parkinson’s research that has been conducted on this protein, and we will discuss what we know about the potential trial. # # # # |
A man on a mission. Source: Goulburnpost
The gentleman in the photo above is named Clyde Campbell.
True blue Aussie, innovative robotics engineer, keen sportsman, and all round nice guy.
Clyde also has Parkinson’s, which was diagnosed in 2009 after he noticed a tremor in his left hand while holding notes at a business meeting. After dealing with the initial shock of this life changing event, he turned his attention to doing something about it.
Clyde simply could not sit still and not do anything about his situation, so he grabbed the bull by the horns and decided to shake things up.
In 2011, Clyde (and his brother Greg) founded a charity called the Shake It Up Australia Foundation:
Since its founding, the foundation has supported 38 Parkinson’s research projects across 12 institutes, with over AUS$11.5 million in funding. In addition, the organisation is a key partner in the Australian Parkinson’s Mission (Click here to read a previous SoPD post on this project).
To learn more about Clyde, watch this video where he shares his story:
This week the Shake It Up Australia Foundation made a big announcement.
What did they say?
The Science of Parkinson's 